Logo image of CLBR

COLOMBIER ACQUISITION CORP-A (CLBR) Stock Fundamental Analysis

NYSE:CLBR - New York Stock Exchange, Inc. - KYG2283U1004 - Common Stock - Currency: USD

14.95  -0.29 (-1.9%)

Premarket: 15.3 +0.35 (+2.34%)

Fundamental Rating

2

CLBR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. While CLBR seems to be doing ok healthwise, there are quite some concerns on its profitability. CLBR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLBR had positive earnings in the past year.
In the past year CLBR has reported a negative cash flow from operations.
CLBR had positive earnings in 4 of the past 5 years.
In the past 5 years CLBR always reported negative operating cash flow.
CLBR Yearly Net Income VS EBIT VS OCF VS FCFCLBR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M

1.2 Ratios

Industry RankSector Rank
ROA 2.25%
ROE 2.35%
ROIC N/A
ROA(3y)2.26%
ROA(5y)N/A
ROE(3y)2.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLBR Yearly ROA, ROE, ROICCLBR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 1 -1 2 3

1.3 Margins

CLBR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLBR Yearly Profit, Operating, Gross MarginsCLBR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for CLBR remains at a similar level compared to 1 year ago.
There is no outstanding debt for CLBR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLBR Yearly Shares OutstandingCLBR Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
CLBR Yearly Total Debt VS Total AssetsCLBR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

CLBR has an Altman-Z score of 23.49. This indicates that CLBR is financially healthy and has little risk of bankruptcy at the moment.
CLBR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.49
ROIC/WACCN/A
WACCN/A
CLBR Yearly LT Debt VS Equity VS FCFCLBR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.34 indicates that CLBR may have some problems paying its short term obligations.
CLBR has a Quick Ratio of 0.34. This is a bad value and indicates that CLBR is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.34
Quick Ratio 0.34
CLBR Yearly Current Assets VS Current LiabilitesCLBR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1289.74% over the past year.
CLBR shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.67% yearly.
EPS 1Y (TTM)1289.74%
EPS 3Y2.67%
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 78.68, the valuation of CLBR can be described as expensive.
Compared to an average S&P500 Price/Earnings ratio of 27.28, CLBR is valued quite expensively.
Industry RankSector Rank
PE 78.68
Fwd PE N/A
CLBR Price Earnings VS Forward Price EarningsCLBR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLBR Per share dataCLBR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLBR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COLOMBIER ACQUISITION CORP-A

NYSE:CLBR (7/2/2025, 8:26:45 PM)

Premarket: 15.3 +0.35 (+2.34%)

14.95

-0.29 (-1.9%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)05-13 2025-05-13
Earnings (Next)08-04 2025-08-04
Inst Owners78.62%
Inst Owner Change-0.63%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap317.69M
Analysts0
Price TargetN/A
Short Float %1.17%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 78.68
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.85
P/tB 1.85
EV/EBITDA N/A
EPS(TTM)0.19
EY1.27%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS8.1
TBVpS8.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.25%
ROE 2.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)2.26%
ROA(5y)N/A
ROE(3y)2.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.34
Quick Ratio 0.34
Altman-Z 23.49
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1289.74%
EPS 3Y2.67%
EPS 5YN/A
EPS Q2Q%-102.94%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-583.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-113.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-113.87%
OCF growth 3YN/A
OCF growth 5YN/A